Gregory MBA - Artelo Biosciences CEO and President
| ARTL Stock | USD 3.41 -0.16 -4.48% |
Insider
Gregory MBA is CEO and President of Artelo Biosciences
| Age | 63 |
| Address | 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075 |
| Phone | 858 925 7049 |
| Web | https://artelobio.com |
Artelo Biosciences Management Efficiency
ARTL has return on total asset (ROA) of -190.09 % which indicates that it has lost $190.09 on every $100 of assets deployed. This is much lower than what is typical in the sector. Similarly, it shows a return on stockholder's equity (ROE) of -1625.11 %, which implies that the business failed to generate returns adequate to cover equity costs.Similar Executives
| Found 10 records | INSIDER Age | ||
| Michael Breen | GT Biopharma | 62 | |
| MPH MBA | GT Biopharma | N/A | |
| Manu Ohri | GT Biopharma | 69 | |
| Andrew Slee | Protagenic Therapeutics | 76 | |
| Gregory MD | GT Biopharma | 66 | |
| PharmD MBA | GT Biopharma | N/A | |
| Jeffrey MD | GT Biopharma | N/A | |
| David Lovejoy | Protagenic Therapeutics | N/A | |
| Oz CPA | Scisparc | 39 | |
| Chester III | Revelation Biosciences | 46 | |
Management Performance
| Return On Equity | -16.25 | ||||
| Return On Asset | -1.9 |
Artelo Biosciences Leadership Team
Elected by the shareholders, the Artelo Biosciences' board of directors comprises two types of representatives: Artelo Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artelo. The board's role is to monitor Artelo Biosciences' management team and ensure that shareholders' interests are well served. Artelo Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artelo Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Gorgas, President CEO, Secretary & Director | ||
| Mark CPA, Treasurer, CFO | ||
| Mark Spring, CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | ||
| Jason Baybutt, Senior Vice President of Finance | ||
| Andrew Yates, Senior VP & Chief Scientific Officer | ||
| Steven Reich, Chief Officer | ||
| Steven MD, Chief Medical Officer | ||
| Gregory MBA, CEO and President |
Artelo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. How does Artelo Biosciences perform across key financial metrics? Although profit is still the single most important financial element of any organization, multiple performance indicators identify the equity that they will appreciate over time.
| Return On Equity | -16.25 | ||||
| Return On Asset | -1.9 | ||||
| Current Valuation | 3.29 M | ||||
| Shares Outstanding | 938.13 K | ||||
| Shares Owned By Insiders | 10.72 % | ||||
| Shares Owned By Institutions | 4.91 % | ||||
| Number Of Shares Shorted | 250.96 K | ||||
| Price To Earnings | 16.31 X | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | -12.54 M |
Building Efficient Market-Beating Portfolios Requires Time, Education, and a Lot of Computing Power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by applying machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try Portfolio Prophet